GenFleet and BeiGene partner for Phase Ib/II lymphoma treatment trial

GenFleet Therapeutics has signed a clinical trial collaboration and supply agreement with BeiGene Switzerland to commence a Phase Ib/II clinical …

Aurion doses first subject in Phase I/II corneal oedema trial in Canada

Aurion Biotech has dosed the first Canadian subject in the Phase I/II ABA-1, CLARA clinical trial of AURN001, a new …

InnoCare doses first subject in Phase Ib NSCLC combination treatment trial

InnoCare Pharma has dosed the first subject in a Phase Ib clinical trial assessing a combination its ICP-189 plus ArriVent …

Bristol Myers Squibb’s Phase III trial of KRAZATI meets endpoints

Bristol Myers Squibb (BMS) has announced that its Phase III KRYSTAL-12 clinical trial of KRAZATI (adagrasib) for treating non-small cell …

Novocure’s TTFields device slows metastasis in NSCLC

Novocure’s Tumor Treating Fields (TTFields) therapy met its primary endpoint in the Phase III METIS trial by slowing the progression …